# Blend Labs, Inc.: financial statements, quarterly

BLND · NYSE · CIK 1855747 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/blnd.md) · [Financials](/companies/blnd/financials.md) · [Filings](/companies/blnd/filings.md) · [Insiders](/companies/blnd/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/blnd/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [40.6](/filings/0001855747-24-000085.md) | [(11.2) d](/filings/0001855747-26-000016.md) | [23.8](/filings/0001855747-25-000041.md) | [28.7](/filings/0001855747-25-000069.md) | [33.1](/filings/0001855747-25-000092.md) | [30.1 d](/filings/0001855747-26-000016.md) | [26.8](/filings/0001855747-26-000042.md) | [31.6](/filings/0001855747-26-000057.md) | [32.7](/filings/0001855747-26-000016.md) | [31.6](/filings/0001855747-26-000057.md) | [30.8](/filings/0001855747-26-000042.md) | [33.8](/filings/0001855747-26-000057.md) |
| Cost of revenue | $m | [18.5](/filings/0001855747-24-000085.md) | [(26.2) d](/filings/0001855747-26-000016.md) | [7.8](/filings/0001855747-25-000041.md) | [8.4](/filings/0001855747-25-000069.md) | [8.6](/filings/0001855747-25-000092.md) | [7.8 d](/filings/0001855747-26-000016.md) | [7.8](/filings/0001855747-26-000042.md) | [8.3](/filings/0001855747-26-000057.md) | [8.4](/filings/0001855747-26-000016.md) | [8.3](/filings/0001855747-26-000057.md) | [7.5](/filings/0001855747-26-000042.md) | [9.0](/filings/0001855747-26-000057.md) |
| Gross profit | $m | [22.1](/filings/0001855747-24-000085.md) | [15.1 d](/filings/0001855747-26-000016.md) | [16.0](/filings/0001855747-25-000041.md) | [20.3](/filings/0001855747-25-000069.md) | [24.5](/filings/0001855747-25-000092.md) | [22.3 d](/filings/0001855747-26-000016.md) | [19.0](/filings/0001855747-26-000042.md) | [23.4](/filings/0001855747-26-000057.md) | [24.3](/filings/0001855747-26-000016.md) | [23.4](/filings/0001855747-26-000057.md) | [23.4](/filings/0001855747-26-000042.md) | [24.9](/filings/0001855747-26-000057.md) |
| Research and development | $m | [18.8](/filings/0001855747-24-000085.md) | [14.1 d](/filings/0001855747-26-000016.md) | [14.2](/filings/0001855747-25-000041.md) | [12.9](/filings/0001855747-25-000069.md) | [10.1](/filings/0001855747-25-000092.md) | [8.9 d](/filings/0001855747-26-000016.md) | [7.8](/filings/0001855747-26-000042.md) | [7.5](/filings/0001855747-26-000057.md) | [8.7](/filings/0001855747-26-000016.md) | [7.5](/filings/0001855747-26-000057.md) | [9.4](/filings/0001855747-26-000042.md) | [8.7](/filings/0001855747-26-000057.md) |
| Operating income | $m | [(36.2)](/filings/0001855747-24-000085.md) | [(9.3) d](/filings/0001855747-26-000016.md) | [(21.2)](/filings/0001855747-25-000041.md) | [(13.1)](/filings/0001855747-25-000069.md) | [(11.3)](/filings/0001855747-25-000092.md) | [(3.3) d](/filings/0001855747-26-000016.md) | [(8.0)](/filings/0001855747-26-000042.md) | [(4.8)](/filings/0001855747-26-000057.md) | [(5.3)](/filings/0001855747-26-000016.md) | [(4.8)](/filings/0001855747-26-000057.md) | [(5.1)](/filings/0001855747-26-000042.md) | [(1.6)](/filings/0001855747-26-000057.md) |
| Interest expense | $m | [8.2](/filings/0001855747-24-000085.md) | [7.1 d](/filings/0001855747-24-000015.md) | [5.1](/filings/0001855747-24-000050.md) | [1.6](/filings/0001855747-24-000071.md) | [0.0](/filings/0001855747-24-000085.md) | [0.0 d](/filings/0001855747-26-000016.md) | [0.0](/filings/0001855747-25-000041.md) | [0.0](/filings/0001855747-25-000069.md) | [0.0](/filings/0001855747-25-000092.md) | [0.0 d](/filings/0001855747-26-000016.md) | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001855747-24-000085.md) | [(0.1) d](/filings/0001855747-26-000016.md) | [0.0](/filings/0001855747-25-000041.md) | [0.0](/filings/0001855747-25-000069.md) | [0.0](/filings/0001855747-25-000092.md) | [0.0 d](/filings/0001855747-26-000016.md) | [0.0](/filings/0001855747-26-000042.md) | [0.0](/filings/0001855747-26-000057.md) | [0.0](/filings/0001855747-26-000016.md) | [0.0](/filings/0001855747-26-000057.md) | [0.1](/filings/0001855747-26-000042.md) | [0.1](/filings/0001855747-26-000057.md) |
| Net income | $m | [(41.8)](/filings/0001855747-24-000085.md) | [(30.3) d](/filings/0001855747-26-000016.md) | [(20.7)](/filings/0001855747-25-000092.md) | [(19.4)](/filings/0001855747-25-000092.md) | [(2.4)](/filings/0001855747-25-000092.md) | [(0.8) d](/filings/0001855747-26-000016.md) | [(9.5)](/filings/0001855747-26-000057.md) | [(6.8)](/filings/0001855747-26-000057.md) | [12.1](/filings/0001855747-26-000016.md) | [(6.8)](/filings/0001855747-26-000057.md) | [(8.0)](/filings/0001855747-26-000057.md) | [(1.5)](/filings/0001855747-26-000057.md) |
| Diluted EPS | $ per share | [(0.18)](/filings/0001855747-24-000085.md) | not reported | [(0.09)](/filings/0001855747-24-000050.md) | [(0.09)](/filings/0001855747-24-000071.md) | [(0.03)](/filings/0001855747-25-000092.md) | not reported | [(0.06)](/filings/0001855747-26-000042.md) | [(0.04)](/filings/0001855747-26-000057.md) | [0.02](/filings/0001855747-26-000016.md) | not reported | [(0.05)](/filings/0001855747-26-000042.md) | [(0.03)](/filings/0001855747-26-000057.md) |
| Basic EPS | $ per share | [(0.18)](/filings/0001855747-24-000085.md) | not reported | [(0.09)](/filings/0001855747-24-000050.md) | [(0.09)](/filings/0001855747-24-000071.md) | [(0.03)](/filings/0001855747-25-000092.md) | not reported | [(0.06)](/filings/0001855747-26-000042.md) | [(0.04)](/filings/0001855747-26-000057.md) | [0.02](/filings/0001855747-26-000016.md) | not reported | [(0.05)](/filings/0001855747-26-000042.md) | [(0.03)](/filings/0001855747-26-000057.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [84.6](/filings/0001855747-24-000085.md) | [23.5](/filings/0001855747-26-000016.md) | [77.6](/filings/0001855747-25-000041.md) | [41.8](/filings/0001855747-25-000069.md) | [50.6](/filings/0001855747-25-000092.md) | [38.0](/filings/0001855747-26-000016.md) | [56.2](/filings/0001855747-26-000042.md) | [36.5](/filings/0001855747-26-000057.md) | [55.0](/filings/0001855747-26-000016.md) | [45.1](/filings/0001855747-26-000057.md) | [37.4](/filings/0001855747-26-000042.md) | [23.3](/filings/0001855747-26-000057.md) |
| Current assets | $m | [283](/filings/0001855747-23-000073.md) | [170](/filings/0001855747-25-000017.md) | [160](/filings/0001855747-24-000050.md) | [143](/filings/0001855747-24-000071.md) | [146](/filings/0001855747-24-000085.md) | [135](/filings/0001855747-26-000016.md) | [139](/filings/0001855747-26-000016.md) | [126](/filings/0001855747-26-000016.md) | [116](/filings/0001855747-26-000016.md) | [99.8](/filings/0001855747-26-000057.md) | [93.1](/filings/0001855747-26-000042.md) | [75.9](/filings/0001855747-26-000057.md) |
| Total assets | $m | [318](/filings/0001855747-23-000073.md) | [206](/filings/0001855747-25-000017.md) | [202](/filings/0001855747-24-000050.md) | [185](/filings/0001855747-24-000071.md) | [186](/filings/0001855747-24-000085.md) | [178](/filings/0001855747-26-000016.md) | [187](/filings/0001855747-26-000016.md) | [182](/filings/0001855747-26-000016.md) | [189](/filings/0001855747-26-000016.md) | [170](/filings/0001855747-26-000057.md) | [161](/filings/0001855747-26-000042.md) | [144](/filings/0001855747-26-000057.md) |
| Current liabilities | $m | [36.8](/filings/0001855747-23-000073.md) | [31.6](/filings/0001855747-25-000017.md) | [42.6](/filings/0001855747-24-000050.md) | [41.5](/filings/0001855747-24-000071.md) | [45.2](/filings/0001855747-24-000085.md) | [39.0](/filings/0001855747-26-000016.md) | [57.6](/filings/0001855747-26-000016.md) | [52.4](/filings/0001855747-26-000016.md) | [45.6](/filings/0001855747-26-000016.md) | [39.5](/filings/0001855747-26-000057.md) | [51.5](/filings/0001855747-26-000042.md) | [46.7](/filings/0001855747-26-000057.md) |
| Total liabilities | $m | [267](/filings/0001855747-23-000073.md) | [179](/filings/0001855747-25-000017.md) | [190](/filings/0001855747-24-000050.md) | [48.3](/filings/0001855747-24-000071.md) | [47.5](/filings/0001855747-24-000085.md) | [40.4](/filings/0001855747-26-000016.md) | [58.8](/filings/0001855747-26-000016.md) | [55.0](/filings/0001855747-26-000016.md) | [47.2](/filings/0001855747-26-000016.md) | [41.0](/filings/0001855747-26-000057.md) | [52.9](/filings/0001855747-26-000042.md) | [48.8](/filings/0001855747-26-000057.md) |
| Long-term debt | $m | [219](/filings/0001855747-23-000073.md) | [138](/filings/0001855747-25-000017.md) | [139](/filings/0001855747-24-000050.md) | [0.0](/filings/0001855747-24-000071.md) | [0.0](/filings/0001855747-24-000085.md) | [0.0](/filings/0001855747-26-000016.md) | [0.0](/filings/0001855747-25-000041.md) | [0.0](/filings/0001855747-25-000069.md) | [0.0](/filings/0001855747-26-000016.md) | [0.0](/filings/0001855747-26-000016.md) | not reported | not reported |
| Shareholders' equity | $m | [6.3](/filings/0001855747-24-000085.md) | [(19.2)](/filings/0001855747-26-000016.md) | [(35.8)](/filings/0001855747-25-000092.md) | [(45.5)](/filings/0001855747-25-000092.md) | [(49.6)](/filings/0001855747-25-000092.md) | [(56.4)](/filings/0001855747-26-000057.md) | [(17.2)](/filings/0001855747-26-000057.md) | [(23.1)](/filings/0001855747-26-000057.md) | [(13.4)](/filings/0001855747-26-000016.md) | [(30.5)](/filings/0001855747-26-000057.md) | [(55.9)](/filings/0001855747-26-000057.md) | [(74.4)](/filings/0001855747-26-000057.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(25.9) d](/filings/0001855747-24-000085.md) | [(20.7) d](/filings/0001855747-26-000016.md) | [(3.9)](/filings/0001855747-25-000041.md) | [(6.7) d](/filings/0001855747-25-000069.md) | [2.1 d](/filings/0001855747-25-000092.md) | [(4.6) d](/filings/0001855747-26-000016.md) | [20.1](/filings/0001855747-26-000042.md) | [(6.5) d](/filings/0001855747-26-000057.md) | [(3.6) d](/filings/0001855747-26-000016.md) | [1.5 d](/filings/0001855747-26-000016.md) | [7.4](/filings/0001855747-26-000042.md) | [7.9 d](/filings/0001855747-26-000057.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001855747-24-000085.md) | [(0.5) d](/filings/0001855747-26-000016.md) | [2.0](/filings/0001855747-25-000041.md) | [1.9 d](/filings/0001855747-25-000069.md) | [3.4 d](/filings/0001855747-25-000092.md) | [2.5 d](/filings/0001855747-26-000016.md) | [4.3](/filings/0001855747-26-000042.md) | [3.6 d](/filings/0001855747-26-000057.md) | [2.1 d](/filings/0001855747-26-000016.md) | [1.6 d](/filings/0001855747-26-000016.md) | [1.1](/filings/0001855747-26-000042.md) | [0.8 d](/filings/0001855747-26-000057.md) |
| Share repurchases | $m | not reported | not reported | [0.0](/filings/0001855747-25-000041.md) | [0.0 d](/filings/0001855747-25-000069.md) | [0.0 d](/filings/0001855747-25-000092.md) | [0.0 d](/filings/0001855747-26-000016.md) | [2.6](/filings/0001855747-26-000042.md) | [1.6 d](/filings/0001855747-26-000057.md) | [5.0 d](/filings/0001855747-25-000092.md) | [15.7 d](/filings/0001855747-26-000016.md) | [16.8](/filings/0001855747-26-000042.md) | [20.4 d](/filings/0001855747-26-000057.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [235](/filings/0001855747-23-000073.md) | [241](/filings/0001855747-24-000050.md) | [244](/filings/0001855747-24-000071.md) | [246](/filings/0001855747-24-000085.md) | [251](/filings/0001855747-25-000041.md) | [253](/filings/0001855747-25-000069.md) | [255](/filings/0001855747-25-000092.md) | [259](/filings/0001855747-26-000042.md) | [259](/filings/0001855747-26-000057.md) | [269](/filings/0001855747-26-000016.md) | [256](/filings/0001855747-26-000042.md) | [240](/filings/0001855747-26-000057.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.